ICFG Spain / Boltendahl International advises on the Series A+ funding for ZuriMED
| Target | ZuriMED AG |
| Deal Type | Debt & Equity Financing |
| Buyer | Innosuisse, Pharma CVC, Surgeon Angel investors, Boltendahl Angel investors |
| Territory | SpainSwitzerland |
| Transaction Description | ZuriMED, an innovation-driven Swiss company based in Zurich that spun off in 2015 from the Institute for Biomechanics at ETH Zurich. ZuriMED excels as an innovation engine for soft-tissue repair, driven by a dynamic management team and backed by a network of world-leading scientists, clinicians, and medical industry experts. 15 of these KOLs are also investors in the company. The first product in the pipeline is the Rotator Cuff Repair with FDA clearance expected by Q4 2024. ZuriMED developed the Surgical-Fiberlock instrument which functions as a high-speed surgical “sewing” technology, device protected by many patents at a global level. Boltendahl International Partners, led by Juan Capurro and Charles Depasse acted as lead advisors on the transaction which included assessing the strategic options, coordinating with the Boltendahl Angel Group and supporting the business through to a successful completion. |
| Industry Sector | Healthcare |
| ICFG Office | Madrid |
ICFG member based in Spain led by partners Juan Capurro and Charles Depasse advised Swiss-based ZuriMED on their CHF 5 million Series A+ funding round to accelerate market entry in the US. The round was jointly led by a group of Boltendahl related investors, a Swiss VC and another group of US based surgeon investors.
